利拉鲁肽对肥胖型糖尿病患者的临床疗效  

Clinical efficacy of liraglutide in patients with obese diabetes

作　　者：郑鑫兴 江浩[1] 梁嘉 黎日伦 ZHENG Xin-xing;JIANG Hao;LIANG Jia(Department of Endocrinology,Guangdong Xinyi People’s Hospital,Xinyi 525300,China)

机构地区：[1]广东省信宜市人民医院内分泌科,525300

出　　处：《中国现代药物应用》2019年第2期85-86,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨利拉鲁肽对肥胖型糖尿病患者的临床效果。方法 80例肥胖型糖尿病患者,随机分为观察组和对照组,每组40例。观察组采用利拉鲁肽皮下注射进行治疗,对照组采用胰岛素泵连续泵入进行治疗。比较两组患者的临床效果。结果治疗后,观察组患者的空腹血糖、餐后2 h血糖、糖化血红蛋白水平分别为(7.51±0.75)mmol/L、(9.14±0.92)mmol/L、(7.11±1.02)%均优于对照组的(8.11±0.64)mmol/L、(10.16±1.36)mmol/L、(8.31±1.07)%,差异具有统计学意义(P<0.05)。结论肥胖型糖尿病患者采用利拉鲁肽进行治疗,不仅可以有效的控制患者血糖,还可以降低患者机体的腰围、体重,也是胰岛素治疗中的一种较为强化的治疗手段,为肥胖型糖尿病患者提供了新型的治疗途径,值得临床应用推广。Objective To discuss the clinical effect of liraglutide in patients with obese diabetes Methods A total of 80 patients with obese diabetes were randomly divided into observation group and control group,with 40 cases in each group.The observation group was treated with subcutaneous injection of liraglutide,and the control group was treated with insulin pump continuous pumping.The clinical effect in two groups was compared.Results After treatment,the observation group had fasting blood glucose,2 h postprandial blood glucose,and glycated hemoglobin level respectively as(7.51±0.75)mmol/L,(9.14±0.92)mmol/L and(7.11±1.02)%than(8.11±0.64)mmol/L,(10.16±1.36)mmol/L and(8.31±1.07)%in the control group,and their difference was statistically significant(P<0.05).Conclusion Obese diabetes patients treated with liraglutide can not only effectively control the patient’s blood glucose,but also reduce the waist circumference and body weight of the patient’s body.It is also a more intensive treatment in insulin therapy.It provides a new treatment approach for obese diabetic patients and is worthy of clinical application and promotion.

关 键 词：利拉鲁肽 肥胖型糖尿病 临床疗效 

分 类 号：R587.1[医药卫生—内分泌]